Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma

D Berton-Rigaud… - International Journal of …, 2014 - ijgc.bmj.com
Carcinosarcomas (also known as malignant mixed müllerian tumors) are rare and highly
aggressive epithelial malignancies that contain both malignant sarcomatous and …

Dostarlimab for primary advanced or recurrent endometrial cancer

MR Mirza, DM Chase, BM Slomovitz… - … England Journal of …, 2023 - Mass Medical Soc
Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …

Pembrolizumab plus chemotherapy in advanced endometrial cancer

RN Eskander, MW Sill, L Beffa, RG Moore… - … England Journal of …, 2023 - Mass Medical Soc
Background Standard first-line chemotherapy for endometrial cancer is paclitaxel plus
carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear …

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma

F Amant, A Floquet, M Friedlander… - International Journal of …, 2014 - ijgc.bmj.com
Endometrial stromal sarcoma (ESS) accounts for approximately 20% of all uterine sarcomas
and presents, at a mean age, around 50 years of age. Half of the patients are …

[HTML][HTML] Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer

D Matei, V Filiaci, ME Randall, D Mutch… - … England Journal of …, 2019 - Mass Medical Soc
Abstract Background Stage III or IVA endometrial cancer carries a significant risk of systemic
and locoregional recurrence. Methods In this randomized phase 3 trial, we tested whether 6 …

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

JM Schilder, AM Thompson, PD DePriest… - Gynecologic …, 2002 - Elsevier
Objectives. The purpose of this study was to determine the recurrence rate, survival, and
pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer …

Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology

RJ Morgan, DK Armstrong, RD Alvarez… - Journal of the National …, 2016 - jnccn.org
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common
ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and …

[PDF][PDF] Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis

EA Kidd, BA Siegel, F Dehdashti, JS Rader, DG Mutch… - J Clin Oncol, 2010 - academia.edu
Purpose A previous retrospective study demonstrated that positron emission tomography
with [18F] fluorodeoxyglucose (FDG-PET) was more sensitive than computed tomography …

[HTML][HTML] Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209)

DS Miller, VL Filiaci, RS Mannel, DE Cohn… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment
of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic …

A multi-institutional review of outcomes of endometrial stromal sarcoma

CA Leath III, WK Huh, J Hyde Jr, DE Cohn… - Gynecologic …, 2007 - Elsevier
OBJECTIVE.: To compare the clinical behavior and outcomes of low-and high-grade
endometrial stromal sarcomas (LGESS and HGESS), respectively. METHODS.: Patients with …